197 related articles for article (PubMed ID: 23509972)
1. Perlecan domain V therapy for stroke: a beacon of hope?
Bix GJ
ACS Chem Neurosci; 2013 Mar; 4(3):370-4. PubMed ID: 23509972
[TBL] [Abstract][Full Text] [Related]
2. Perlecan Domain-V Enhances Neurogenic Brain Repair After Stroke in Mice.
Trout AL; Kahle MP; Roberts JM; Marcelo A; de Hoog L; Boychuk JA; Grupke SL; Berretta A; Gowing EK; Boychuk CR; Gorman AA; Edwards DN; Rutkai I; Biose IJ; Ishibashi-Ueda H; Ihara M; Smith BN; Clarkson AN; Bix GJ
Transl Stroke Res; 2021 Feb; 12(1):72-86. PubMed ID: 32253702
[TBL] [Abstract][Full Text] [Related]
3. Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents.
Lee B; Clarke D; Al Ahmad A; Kahle M; Parham C; Auckland L; Shaw C; Fidanboylu M; Orr AW; Ogunshola O; Fertala A; Thomas SA; Bix GJ
J Clin Invest; 2011 Aug; 121(8):3005-23. PubMed ID: 21747167
[TBL] [Abstract][Full Text] [Related]
4. Investigating the role of perlecan domain V in post-ischemic cerebral angiogenesis.
Marcelo A; Bix G
Methods Mol Biol; 2014; 1135():331-41. PubMed ID: 24510876
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 1 alpha administration is neuroprotective and neuro-restorative following experimental ischemic stroke.
Salmeron KE; Maniskas ME; Edwards DN; Wong R; Rajkovic I; Trout A; Rahman AA; Hamilton S; Fraser JF; Pinteaux E; Bix GJ
J Neuroinflammation; 2019 Nov; 16(1):222. PubMed ID: 31727174
[TBL] [Abstract][Full Text] [Related]
6. Perlecan domain V is neuroprotective and affords functional improvement in a photothrombotic stroke model in young and aged mice.
Bix GJ; Gowing EK; Clarkson AN
Transl Stroke Res; 2013 Oct; 4(5):515-23. PubMed ID: 24323378
[TBL] [Abstract][Full Text] [Related]
7. The neuroprotective role of the brain opioid system in stroke injury.
Vaidya B; Sifat AE; Karamyan VT; Abbruscato TJ
Drug Discov Today; 2018 Jul; 23(7):1385-1395. PubMed ID: 29501910
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection & mechanism of ethanol in stroke and traumatic brain injury therapy: new prospects for an ancient drug.
Asmaro K; Fu P; Ding Y
Curr Drug Targets; 2013 Jan; 14(1):74-80. PubMed ID: 23170798
[TBL] [Abstract][Full Text] [Related]
9. A beacon of hope in stroke therapy-Blockade of pathologically activated cellular events in excitotoxic neuronal death as potential neuroprotective strategies.
Hoque A; Hossain MI; Ameen SS; Ang CS; Williamson N; Ng DC; Chueh AC; Roulston C; Cheng HC
Pharmacol Ther; 2016 Apr; 160():159-79. PubMed ID: 26899498
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targets for neuroprotection in acute ischemic stroke: lost in translation?
Stankowski JN; Gupta R
Antioxid Redox Signal; 2011 May; 14(10):1841-51. PubMed ID: 20626319
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine A, a Potential Therapy of Ischemic Reperfusion Injury. A Common History for Heart and Brain.
Nighoghossian N; Ovize M; Mewton N; Ong E; Cho TH
Cerebrovasc Dis; 2016; 42(5-6):309-318. PubMed ID: 27245840
[TBL] [Abstract][Full Text] [Related]
12. Disrupted Ionic Homeostasis in Ischemic Stroke and New Therapeutic Targets.
Hu HJ; Song M
J Stroke Cerebrovasc Dis; 2017 Dec; 26(12):2706-2719. PubMed ID: 29054733
[TBL] [Abstract][Full Text] [Related]
13. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.
Menn B; Bach S; Blevins TL; Campbell M; Meijer L; Timsit S
PLoS One; 2010 Aug; 5(8):e12117. PubMed ID: 20711428
[TBL] [Abstract][Full Text] [Related]
14. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke.
Morales JR; Ballesteros I; Deniz JM; Hurtado O; Vivancos J; Nombela F; Lizasoain I; Castrillo A; Moro MA
Circulation; 2008 Sep; 118(14):1450-9. PubMed ID: 18794391
[TBL] [Abstract][Full Text] [Related]
15. Aging causes exacerbated ischemic brain injury and failure of sevoflurane post-conditioning: role of B-cell lymphoma-2.
Dong P; Zhao J; Zhang Y; Dong J; Zhang L; Li D; Li L; Zhang X; Yang B; Lei W
Neuroscience; 2014 Sep; 275():2-11. PubMed ID: 24929064
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection for ischaemic stroke: current status and challenges.
Moretti A; Ferrari F; Villa RF
Pharmacol Ther; 2015 Feb; 146():23-34. PubMed ID: 25196155
[TBL] [Abstract][Full Text] [Related]
17. Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke.
Clausen BH; Lambertsen KL; Dagnæs-Hansen F; Babcock AA; von Linstow CU; Meldgaard M; Kristensen BW; Deierborg T; Finsen B
Acta Neuropathol; 2016 May; 131(5):775-91. PubMed ID: 26860727
[TBL] [Abstract][Full Text] [Related]
18. Poly-arginine and arginine-rich peptides are neuroprotective in stroke models.
Meloni BP; Brookes LM; Clark VW; Cross JL; Edwards AB; Anderton RS; Hopkins RM; Hoffmann K; Knuckey NW
J Cereb Blood Flow Metab; 2015 Jun; 35(6):993-1004. PubMed ID: 25669902
[TBL] [Abstract][Full Text] [Related]
19. Stroke research at a crossroad: asking the brain for directions.
Iadecola C; Anrather J
Nat Neurosci; 2011 Oct; 14(11):1363-8. PubMed ID: 22030546
[TBL] [Abstract][Full Text] [Related]
20. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window.
Belayev L; Liu Y; Zhao W; Busto R; Ginsberg MD
Stroke; 2001 Feb; 32(2):553-60. PubMed ID: 11157196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
